Latest news with #MaunaKeaTechnologies
Yahoo
a day ago
- Business
- Yahoo
Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Article L233-8-II of the Commercial Code Article 223-16 of the General Regulations of the AMF PARIS, June 05, 2025--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Paris:ALMKT): Listing: Euronext Growth ParisISIN code: FR0010609263, Ticker: ALMKTWebsite: Date Number of shares comprising the capital in circulation Total number of voting rights Gross Total (1) Net Total (2) May 31, 2025 74,989,997 76,077,471 76,077,471 Including 1,200,000 new shares issued during the month as part of the equity financing facility (see press releases published on July 25, 2024 and April 24, 2025). (1) The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Article 223-11 of the General Regulations of the AMF, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights. (2) The net number of voting rights (or voting rights "exercisable in General Meeting") is calculated without considering the shares with suspended voting rights. It is published for proper public information in accordance with the AMF recommendation of July 17, 2007. *** About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit View source version on Contacts Mauna Kea Technologies investors@ NewCap - Investor Relations Aurélie Manavarere / Thomas Grojean+33 (0)1 44 71 94 94maunakea@
Yahoo
a day ago
- Business
- Yahoo
Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 5, 2025
All the resolutions proposed by the Board of Directors were adopted PARIS & BOSTON, June 05, 2025--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, held its Combined General Meeting of June 5, 2025, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of Directors and CEO. With a quorum of 38.5%, all the resolutions proposed by the Board of Directors have been adopted. Among the main resolutions approved were the adoption of the annual and consolidated financial statements for the year ended December 31, 2024, the allocation of the 2024 net result, as well as delegations granted to the Board of Directors related to financial transactions. Details on the vote results are available on the Company's website. About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit Disclaimer This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website ( as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document. View source version on Contacts Mauna Kea Technologies investors@ NewCap - Investor Relations Aurélie Manavarere / Thomas Grojean+33 (0)1 44 71 94 94maunakea@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
a day ago
- Business
- Business Wire
Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 5, 2025
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio ®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, held its Combined General Meeting of June 5, 2025, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of Directors and CEO. With a quorum of 38.5%, all the resolutions proposed by the Board of Directors have been adopted. Among the main resolutions approved were the adoption of the annual and consolidated financial statements for the year ended December 31, 2024, the allocation of the 2024 net result, as well as delegations granted to the Board of Directors related to financial transactions. Details on the vote results are available on the Company's website. About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio ®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio ® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit Disclaimer This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website ( as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
Business Wire
4 days ago
- Health
- Business Wire
Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio ®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces a significant advancement with the results of a landmark study published in the peer-reviewed journal Pancreatology. The research, titled ' Towards Automating Risk Stratification of Intraductal Papillary Mucinous Neoplasms: Artificial Intelligence Advances Beyond Human Expertise with Confocal Laser Endomicroscopy 2 ', demonstrates that Artificial Intelligence (AI) model combined with Cellvizio ® needle-based confocal laser endomicroscopy (nCLE) technology significantly outperforms human experts in risk stratification of Intraductal Papillary Mucinous Neoplasms (IPMNs), a common type of pancreatic cyst. The study aimed to compare the performance of 16 nCLE human experts with a novel AI algorithm (nCLE-AI) specifically designed for the sub-classification of a type of pancreatic cystic lesion with malignant potential. These findings build on the CLIMB study data presented this year at DDW, which demonstrated strong diagnostic performance of needle-based confocal laser endomicroscopy in differentiating benign from malignant or pre-malignant pancreatic cysts. Indeed, the latest results from the CLIMB study -spanning 17 endosonographers across 14 centers - have further reinforced the significantly superior diagnostic accuracy of Endoscopic Ultrasound-guided nCLE (EUS-nCLE) compared to the current standard of care 3. 'This study marks a pivotal moment in our ability to accurately risk stratify pancreatic cysts. The nCLE-AI model has shown remarkable potential to not only enhance diagnostic accuracy beyond current expert capabilities but also to standardize the interpretation of nCLE imaging," said Dr. Somashekar (Som) Krishna, Professor of Medicine and Director of Advanced Endoscopy at The Ohio State University Wexner Medical Center, lead author of the publication."By providing a more precise and objective assessment, this technology can significantly aid clinical decision-making, helping to ensure that patients at high risk receive timely intervention while those with low-risk cysts may avoid unnecessary surveillance or surgery." The results of the study on risk stratification associated with IPMNs cysts with malignant potential, detailed in the table below, show that the nCLE-AI model combined with revised Fukuoka Criteria achieves an Area Under the Curve (AUC) of 0.85, with a sensitivity of 78% and a specificity of 78%. This performance is significantly superior to that of human experts using the same criteria (AUC 0.64; p<0.01) and represents an improvement over the nCLE-AI model alone (p=0.02), clearly demonstrating the superiority of the AI-augmented approach for enhancing the detection of malignant cysts that need immediate intervention. The AI model continues to improve rapidly with additional nCLE sequences and data. Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies, stated:"These latest results, published by a group of highly skilled interventional endoscopists from multiple countries and institutions, under the exceptional leadership of Dr. Krishna, materialize our vision of nCLE enhanced by AI models, whether developed internally or by academic partners. Adding AI will certainly lead to a broader adoption of nCLE in the community of interventional endoscopists but will also open the door to risk stratification strategies, which are completely absent in today's standard of care. This strongly reinforces our conviction that nCLE is playing a pivotal role in the diagnosis and management of patients at risk of pancreatic cancer." About pancreatic cysts The prevalence of pancreatic cystic lesions in the adult asymptomatic population ranges from 2.4% to 24.3%. The large majority of pancreatic cystic lesions are discovered through incidental imaging, and it is estimated that 40% of cysts with no risk of carcinogenesis are operated on unnecessarily. More accurate classification methods, including risk stratification, are therefore needed earlier in the patient's diagnostic workup. Conventional diagnostic testing involves performing an endoscopic ultrasound (EUS) and then collecting and testing the cyst fluid through fine needle aspiration (FNA). In some advanced facilities, next generation sequencing (NGS) of cellular DNA may be performed to provide additional data. Although most facilities employ a combination of a range of conventional diagnostic methods, sensitivity, specificity, and accuracy remain insufficient, potentially exposing patients to misclassified cysts and unneeded surgical procedures About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio ®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio ® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit Disclaimer This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website ( as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document. ______________________________ 1 2 3
Business Wire
21-05-2025
- Business
- Business Wire
Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, provides an update on the safeguard proceedings initiated on March 31, 2025 1, as well as on the progress of its strategic discussions and operational developments. This announcement is part of the Company's commitment to maintaining ongoing transparency with its shareholders and partners during the ongoing process. Since the initiation of this safeguard proceedings, the Company has engaged in constructive discussions with its financial partners to identify the most appropriate options for achieving a sustainable solution to the current situation. In parallel, the Company is actively pursuing the exclusive negotiations announced on April 1 st, 2025, with a major healthcare player, aiming to finalize a licensing agreement for Cellvizio® technology in a high-potential therapeutic area. These discussions are progressing constructively and could represent a major strategic milestone for the Company's clinical and commercial development. On the operational front, Mauna Kea Technologies is experiencing strong momentum with its CellTolerance franchise. The symbolic milestone of 1,500 procedures has been surpassed, demonstrating the growing adoption of the technology. Several new accounts have recently been onboarded, including prestigious institutions that form a solid foundation for future growth. Among them, a leading center in the United States has already performed over 100 procedures in just a few months and continues to show an upward trend in usage. The Company plans to continue updating on these clinical and commercial advancements in the coming weeks. Finally, Mauna Kea Technologies is actively engaged with several investors to secure the financial visibility required for the safeguard proceedings and the finalization of licensing agreement. These discussions aim to provide the Company with the resources required to execute its long-term growth strategy. Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies, stated: "We are navigating this transition period with full determination and remain strongly committed to equipping the Company for future growth. Our commercial outlook is becoming more tangible each day, both for CellTolerance and our pancreatic cyst application, which are increasingly supported by clinical data and a clear enthusiasm among physicians and patients. The safeguard proceedings provide us with a protective framework ideal for negotiating with our stakeholders and preparing for the Company's redeployment on solid foundations. I am very pleased with the dedication of our teams and am fully committed to shaping a new chapter of strong value creation for the Company. Cellvizio is proving its relevance more than ever today, offering a unique opportunity to improve care for millions of patients while reducing healthcare system costs." *** About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit Disclaimer This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website ( as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
